Lambrinex (Atorvastatin)

Atorvastatin inhibits the enzyme HMG‑CoA reductase in the liver, the key step in cholesterol biosynthesis. This reduces hepatic cholesterol production, leading to increased expression of LDL receptors and enhanced removal of LDL cholesterol from the bloodstream.

The specific dose of Lambrinex is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, age, and renal or hepatic function. Dosage adjustments are individualized and should follow the prescriber’s instructions.

The safety of atorvastatin in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lambrinex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Lambrinex (atorvastatin) is a high‑potency statin with a long half‑life, offering greater LDL‑cholesterol reduction at lower doses compared with some older statins such as pravastatin or simvastatin. Its efficacy and safety profile are well‑documented, making it a common first‑line choice for many patients.

Lambrinex tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date.

Lambrinex is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse reactions include myopathy, potentially progressing to rhabdomyolysis, and severe liver injury. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice or persistent fatigue.

Lambrinex is contraindicated in patients with active liver disease, unexplained persistent elevations of hepatic transaminases, or a known hypersensitivity to atorvastatin or any excipients. Caution is also advised for individuals taking strong CYP3A4 inhibitors.